News & Events

Announcement

1 February 2010

Proacta Inc Updates the PR104 Phase II Program

San Diego, CA, February 1, 2010 -- Proacta Inc, a clinical stage biotechnology company, today announced a new Phase I/II trial of PR104 in Acute Myeloid Leukemia (AML). This study is designed to evaluate PR104 in patients with refractory/relapsed AML, and determine a range of optimal individualized doses based on a patient's important prognostic factors. This information will prove valuable in directing the future clinical development of PR104 in patients with AML.

Proacta has also announced the closure of a randomized phase II trial of PR104 in Non-Small Cell Lung Cancer (NSCLC), and one in patients with Hepatocellular carcinoma (HCC). The trial in patients with NSLC evaluated the combination of PR104 with docetaxel in patients with relapsed/refractory NSCLC. This trial failed to demonstrate sufficient efficacy for the PR104/docetaxel combination to justify further development. The trial in HCC evaluated the toxicity of PR104 when combined with sorafenib. In this trial the combination of PR104 and sorafenib was not sufficiently well tolerated.

About Proacta
Proacta Inc is a clinical stage biotechnology company that discovers and develops innovative small molecule prodrugs that address critical, unmet needs in oncology. Proacta's initial programs are focused on developing prodrugs that are selectively activated under hypoxic conditions within a solid tumor. The company's scientific founders are at the University of Auckland, New Zealand, and Stanford University in the United States. Proacta, Inc is headquartered in San Diego, California and has a wholly-owned subsidiary, Proacta Therapeutics Ltd, located in Auckland, New Zealand where drug discovery efforts are located. www.proacta.com